DILTIAZEM HYDROCHLORIDE
Total Payments
$228,268
Transactions
7
Doctors
3
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $227,158 | 4 | 0 |
| 2020 | $1,110 | 3 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $227,158 | 4 | 99.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,110 | 3 | 0.5% |
Payments by Type
Research
$227,158
4 transactions
General
$1,110
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DILT-CAR-1001 | Mylan Pharmaceuticals Inc. | $227,158 | 0 |
Ad
Manufacturing Companies
- Mylan Pharmaceuticals Inc. $227,158
- PFIZER INC. $1,110
Product Information
- Type Drug
- Total Payments $228,268
- Total Doctors 3
- Transactions 7
About DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE is a drug associated with $228,268 in payments to 3 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Pharmaceuticals Inc..
Payment data is available from 2020 to 2022. In 2022, $227,158 was paid across 4 transactions to 0 doctors.
The most common payment nature for DILTIAZEM HYDROCHLORIDE is "Unspecified" ($227,158, 99.5% of total).
DILTIAZEM HYDROCHLORIDE is associated with 1 research study, including "DILT-CAR-1001" ($227,158).